NUVL [NASD]
Nuvalent, Inc.
Index- P/E- EPS (ttm)-1.51 Insider Own5.10% Shs Outstand48.41M Perf Week-1.08%
Market Cap1.65B Forward P/E- EPS next Y-2.60 Insider Trans25.04% Shs Float46.09M Perf Month-8.90%
Income-73.00M PEG- EPS next Q-0.48 Inst Own89.20% Short Float / Ratio7.07% / 16.55 Perf Quarter0.22%
Sales- P/S- EPS this Y-584.20% Inst Trans-1.21% Short Interest3.26M Perf Half Y71.70%
Book/sh4.89 P/B6.12 EPS next Y-33.30% ROA-24.30% Target Price43.50 Perf Year146.55%
Cash/sh4.37 P/C6.85 EPS next 5Y- ROE-25.20% 52W Range7.09 - 40.43 Perf YTD-0.49%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-26.70% Beta-
Dividend %- Quick Ratio18.90 Sales past 5Y- Gross Margin- 52W Low317.98% ATR2.00
Employees57 Current Ratio18.90 Sales Q/Q- Oper. Margin- RSI (14)50.46 Volatility7.39% 7.38%
OptionableYes Debt/Eq0.00 EPS Q/Q-5.10% Profit Margin- Rel Volume0.10 Prev Close29.93
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume197.03K Price29.64
Recom1.80 SMA200.55% SMA50-1.40% SMA20027.92% Volume2,230 Change-0.99%
Jan-18-23Initiated Wedbush Outperform $39
Jun-24-22Initiated BMO Capital Markets Outperform $28
Mar-16-23 06:30AM
Mar-14-23 05:59PM
Mar-01-23 06:30AM
Jan-04-23 06:30AM
Jan-02-23 09:40AM
10:15AM Loading…
Dec-13-22 10:15AM
Dec-12-22 03:44PM
Dec-02-22 08:50AM
Nov-17-22 12:00PM
Nov-10-22 06:30AM
Nov-03-22 08:13PM
Oct-31-22 09:14PM
07:15AM
Oct-28-22 04:18PM
04:06PM
11:10AM Loading…
11:10AM
12:01AM
Oct-26-22 06:30AM
Oct-23-22 09:26AM
Oct-17-22 06:30AM
Oct-06-22 06:30AM
Sep-20-22 10:16AM
Sep-07-22 06:30AM
Sep-01-22 06:30AM
Aug-10-22 06:30AM
Aug-05-22 06:30AM
Aug-03-22 06:30AM
Jul-20-22 06:30AM
Jul-13-22 06:30AM
Jul-01-22 10:52AM
06:30AM Loading…
Jun-21-22 06:30AM
Jun-02-22 06:38AM
May-16-22 09:10AM
May-12-22 06:30AM
Apr-11-22 07:21AM
Apr-08-22 01:15PM
Apr-07-22 06:30AM
Mar-31-22 06:30AM
Mar-29-22 06:30AM
Mar-08-22 05:38PM
Mar-02-22 06:30AM
Feb-03-22 06:30AM
Jan-07-22 06:30AM
Jan-04-22 06:30AM
Nov-10-21 06:30AM
Oct-29-21 09:55AM
Oct-07-21 09:21AM
Sep-08-21 06:30AM
Aug-06-21 06:26PM
Aug-02-21 05:39PM
Jul-28-21 11:22PM
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Miller Deborah AnnChief Legal OfficerMar 15Option Exercise6.892,00013,7802,000Mar 17 04:38 PM
Miller Deborah AnnChief Legal OfficerMar 15Sale28.252,00056,5090Mar 17 04:38 PM
Noci DarleneChief Development OfficerMar 01Option Exercise1.083,0003,2403,000Mar 03 04:35 PM
Noci DarleneChief Development OfficerMar 01Sale29.883,00089,6460Mar 03 04:35 PM
Miller Deborah AnnChief Legal OfficerFeb 15Option Exercise6.892,00013,7802,000Feb 17 04:19 PM
Miller Deborah AnnChief Legal OfficerFeb 15Sale29.562,00059,1270Feb 17 04:19 PM
Noci DarleneChief Development OfficerFeb 02Option Exercise1.083,0003,2403,000Feb 03 04:45 PM
Noci DarleneChief Development OfficerFeb 02Sale29.563,00088,6670Feb 03 04:45 PM
Miller Deborah AnnChief Legal OfficerJan 17Option Exercise6.892,00013,7802,000Jan 19 04:48 PM
Miller Deborah AnnChief Legal OfficerJan 17Sale32.622,00065,2420Jan 19 04:48 PM
Shair MatthewDirectorJan 04Sale28.0418,300513,1061,944,698Jan 06 04:42 PM
Miller Deborah AnnChief Legal OfficerDec 15Option Exercise6.892,00013,7802,000Dec 16 04:48 PM
Noci DarleneChief Development OfficerDec 15Option Exercise1.084,2004,5364,200Dec 16 04:46 PM
Noci DarleneChief Development OfficerDec 15Sale29.914,200125,6350Dec 16 04:46 PM
Miller Deborah AnnChief Legal OfficerDec 15Sale29.982,00059,9550Dec 16 04:48 PM
Shair MatthewDirectorDec 07Sale31.1718,300570,4581,962,998Dec 09 04:45 PM
Miller Deborah AnnChief Legal OfficerNov 15Option Exercise6.892,00013,7802,000Nov 17 04:52 PM
Noci DarleneChief Development OfficerNov 15Option Exercise1.084,2004,5364,200Nov 17 04:46 PM
Noci DarleneChief Development OfficerNov 15Sale31.994,200134,3500Nov 17 04:46 PM
Miller Deborah AnnChief Legal OfficerNov 15Sale31.912,00063,8140Nov 17 04:52 PM
Flynn James EDirector by deputizationNov 03Buy33.50650,00021,775,000650,000Nov 07 06:24 PM
Hack Andrew A. F.DirectorNov 03Buy33.50149,2534,999,9763,577,267Nov 03 04:15 PM
Shair MatthewDirectorNov 03Sale29.6037,9391,123,1151,981,298Nov 04 04:45 PM
Shair MatthewDirectorNov 02Sale32.0495,4553,058,3372,019,237Nov 04 04:45 PM
Miller Deborah AnnChief Legal OfficerOct 28Option Exercise6.898,96861,7908,968Nov 01 05:23 PM
Noci DarleneChief Development OfficerOct 28Option Exercise1.081,0001,0801,000Nov 01 05:24 PM
Miller Deborah AnnChief Legal OfficerOct 28Sale38.868,968348,4700Nov 01 05:23 PM
Noci DarleneChief Development OfficerOct 28Sale40.251,00040,2500Nov 01 05:24 PM
Noci DarleneChief Development OfficerOct 14Option Exercise1.084,2004,5364,200Oct 14 04:48 PM
Noci DarleneChief Development OfficerOct 14Sale21.414,20089,9220Oct 14 04:48 PM
Shair MatthewDirectorOct 07Sale18.7012,613235,8252,114,692Oct 07 04:52 PM
Shair MatthewDirectorOct 06Sale19.008,608163,5522,127,305Oct 07 04:52 PM
Shair MatthewDirectorOct 05Sale19.227,884151,5302,135,913Oct 07 04:52 PM
Noci DarleneChief Development OfficerSep 15Option Exercise1.084,2004,5364,200Sep 16 04:45 PM
Shair MatthewDirectorSep 15Sale18.345,650103,6212,143,797Sep 16 04:48 PM
Noci DarleneChief Development OfficerSep 15Sale18.144,20076,1880Sep 16 04:45 PM
Shair MatthewDirectorSep 14Sale18.3613,151241,4522,149,447Sep 16 04:48 PM
Noci DarleneChief Development OfficerAug 24Option Exercise1.081,6041,7321,604Aug 25 04:15 PM
Noci DarleneChief Development OfficerAug 24Sale17.031,60427,3160Aug 25 04:15 PM
Noci DarleneChief Development OfficerAug 15Option Exercise1.082,5962,8042,596Aug 17 04:17 PM
Noci DarleneChief Development OfficerAug 15Sale17.022,59644,1840Aug 17 04:17 PM
Noci DarleneChief Development OfficerJul 19Option Exercise1.08318343318Jul 19 05:01 PM
Noci DarleneChief Development OfficerJul 19Sale17.023185,4120Jul 19 05:01 PM
Noci DarleneChief Development OfficerJul 18Option Exercise1.08100108100Jul 19 05:01 PM
Noci DarleneChief Development OfficerJul 18Sale17.071001,7070Jul 19 05:01 PM
Noci DarleneChief Development OfficerJul 15Option Exercise1.083,7824,0853,782Jul 19 05:01 PM
Noci DarleneChief Development OfficerJul 15Sale17.293,78265,3790Jul 19 05:01 PM
Shair MatthewDirectorJul 15Sale18.292,00036,5802,162,598Jul 15 04:51 PM
Shair MatthewDirectorJul 13Sale18.251001,8252,164,598Jul 15 04:51 PM
Noci DarleneSee RemarksJul 07Option Exercise1.0816,80018,14416,800Jul 08 04:17 PM
Noci DarleneSee RemarksJul 07Sale17.6116,800295,8480Jul 08 04:17 PM
Turner Christopher DurantChief Medical OfficerMay 17Option Exercise6.8914,51399,99514,513May 19 04:36 PM